Clinical trial
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate…
NCT00427921 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00427921 |
|---|---|
| Title | Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS) |
| Official title | A Multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS) |
| Acronym | ACCESS |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological |
| Interventions | adalimumab |
| Enrollment | 304 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Jan 29, 2007 |
| Last update posted | Nov 20, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: